Romosozumab plus alendronate led to a greater improvement in bone strength than alendronate alone in postmenopausal women ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance ...

(Reuters) - President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Nancy A. Grygiel, Senior Vice President and Chief Compliance Officer at Amgen Inc . (NASDAQ:AMGN), recently sold shares of the company's common stock. According to a filing with the Securities and ...

Researchers observed improvements in rates of burnout and work-life integration challenges among a cohort of U.S. medical oncology fellows in 2023 vs. 2013, but challenges remain, according to survey ...